ArticleTranslational cancer research2026
Stigmasterol reverses rituximab resistance in diffuse large B-cell lymphoma via the MAPK1 signaling pathway.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rituximab (RIT) resistance significantly hampers the treatment efficacy in diffuse large B-cell lymphoma (DLBCL), leading to poor prognosis. We aim to investigate the potential of stigmasterol, a natural compound, to reverse RIT resistance in DLBCL through modulation of the mitogen-activated protein kinase 1 (MAPK1) signaling pathway. Methods: The RIT-resistant DLBCL model, Raji-4RH cells, was established by prolonged exposure to increasing concentrations of RIT. The effects of stigmasterol on cell viability, proliferation, migration, and invasion were assessed using Cell Counting Kit-8 (CCK-8) assays, 5-ethynyl-2'-deoxyuridine (EdU) staining, and Transwell assays. Additionally, the role of MAPK1 signaling in stigmasterol's mechanism of action was evaluated by overexpressing MAPK1 in Raji-4RH cells, and the expression of key multidrug resistance (MDR) proteins was analyzed. Results: Stigmasterol effectively reversed RIT resistance by inhibiting cell proliferation, migration, and invasion. It induced G0/G1 cell cycle arrest and apoptosis, significantly downregulated MDR proteins P-gp, MRP5, and BCRP, and inhibited MAPK1 phosphorylation. The anti-resistance effects of stigmasterol were partially reversed by MAPK1 overexpression, confirming that MAPK1 signaling plays a critical role in its mechanism. Conclusions: Stigmasterol significantly reverses RIT resistance in DLBCL by inhibiting MAPK1 phosphorylation and downregulating MDR protein expression. These findings provide new insights into overcoming RIT resistance and support the potential of stigmasterol as a therapeutic strategy for refractory DLBCL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.